TG Therapeutics raises 2026 revenue guidance as Q2 revenue hits $240.3 million
TG Therapeutics reported second quarter 2026 total revenue of $240.3 million, up from $141.1 million a year earlier, and raised its full-year 2026 total global revenue target to approximately $950 million. Net income fell to $7.8 million from $28.2 million as research and development and selling, general and administrative expenses rose sharply, so higher sales did not translate into higher profit.
Key points
- Q2 2026 total revenue was $240.3 million, versus $141.1 million in Q2 2025; BRIUMVI U.S. net product revenue was $227.7 million.
- Q2 2026 net income was $7.8 million ($0.05 diluted per share), versus $28.2 million ($0.17 diluted per share) in Q2 2025.
- Q2 2026 R&D expense was $95.3 million and SG&A expense was $82.1 million, versus $31.8 million and $55.6 million a year earlier.
- Full-year 2026 targets were raised: total global revenue to approximately $950 million and BRIUMVI U.S. net product revenue to approximately $890 to $905 million.
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.